Vaccinia virus (VV) and other orthopoxviruses express a soluble type I interferon (IFN) receptor that for VV strain Western Reserve is encoded by gene B18R. The 80-85 kDa glycoprotein is related to the interleukin-1 receptors and is a member of the immunoglobulin superfamily, unlike other type I IFN receptors, which belong to the class II cytokine receptor family. The receptor has high affinity (KD, 174 PM) for human IFNa and, unlike other type I IFN receptors, has broad species specificity, binding to human, rabbit, bovine, rat, and mouse type I IFNs. This may have aided VV replication in multiple host species during evolution. A VV B18R deletion mutant is attenuated in a murine intranasal model. This type I IFN receptor represents the fourth VV protein that interferes with IFN and the fourth soluble cytokine receptor expressed by poxviruses.
Introduction lnterferons (IFNs) are a heterogeneous family of cytokines that were initially defined by their ability to induce resistance to viral infection (Isaacs and Lindermann, 1957) . The various IFNa subtypes and IFNP (type I IFNs) share sequence similarity and bind common, species-specific receptors on host cells (for reviews, see Peska and Langer, 1987; Callard and Gearing, 1994) . IFNy (type II IFN) binds to a different receptor (Aguet et al., 1988) . In addition to their antiviral effects, IFNs exhibit other biological properties, including regulation of cellular differentiation, proliferation, and immunomodulation.
Two human type I IFN receptors have been characterized. By use of a gene transfer approach, a 95-110 kDa type I membraneglycoprotein was identified that mediates responses to IFNa8 but not to other human IFNa subtypes or to IFNp (Uze et al., 1990) . More recently, a second type I IFN receptor was cloned after the identification, purification, and sequence analysis of a 40 kDa soluble form of the receptor. The membrane-associated form is a 51 kDa glycoprotein that is disulphide-bonded into a 102 kDa homodimer that binds to most IFNa subtypes and to lFNf3 (Novick et al., 1994) . A mouse IFNa receptor related to the human 95-110 kDa receptor has also been cloned (Uze et al., 1992) that mediates the activities of all the mouse type I IFN subspecies. The type I IFN receptors possess two or four fibronectin type Ill domains and belong to the class II cytokine receptor family (CRFP) that includes the receptors for IFNy and interleukin (IL)-10 and the CRF2-4 gene product. These exhibit 200/o-30% amino acid identity and share common motifs, including two cysteine pairs and conserved proline, tryptophan, and tyrosine residues (Callard and Gearing, 1994) .
Targeted deletion of the mouse type I IFN receptor has revealed that the type I IFN system is essential for host defense against some viruses. Mutant mice became 1 06-fold to lo'-fold more sensitive to vesicular stomatitis virus and Semliki Forest virus than normal mice (Muller et al., 1994) . In contrast, inactivation of the type II IFN system had no effect on infection with these viruses. However, functional type I and type II IFN systems are required for defense against lymphocytic choriomeningitis virus and vaccinia virus (VV) (Muller et al., 1994) .
VV is the prototypic member of the poxvirus family of cytoplasmic DNA viruses and is the live vaccine used to eradicate smallpox (Fenner et al., 1988) . The 191 kbp viral genome has approximately 200 genes (Goebel et al., 1990; Johnson et al., 1993) and isorganized with essential genes, such as those encoding enzymes required for replication and transcription, clustered toward the genome center, whereas nonessential genes influencing host range and virulence map toward the termini. Several of these latter genes encode proteins involved in the evasion of the host immune response to infection (Smith, 1993) .
IFN is important for protection against poxvirus infections. Mice with a targeted disruption of the type I or type II IFN system are more susceptible to infection by VV, despite a normal cytotoxic T cell response (Dalton et al., 1993; Huang et al., 1993; Muller et al., 1994) . Treatment of mousepox virus-infected mice with neutralizing antibodies to either type I or type II IFN resulted in defective clearance of virus (Karupiah et al., 1993a) , whereas treatment of mice with IFN prior to infection with VV abrogates the infection (Rodriguez et al., 1991) . Furthermore, athymic nude mice infected with a recombinant VV expressing IFNy recovered from infection, whereas mice infected with a wild-type W died (Kohonen-Corish et al., 1990) . Lastly, the inhibition of nitricoxidesynthasein mice, which mediates the antiviral activity of IFNT, converts a resolving infection into fulminant mousepox (Karupiah et al., 1993b) .
Poxviruses have several strategies to counteract the action of IFN. The VV E3L protein competitively binds doublestranded RNA (dsRNA) and prevents the activation of the IFN-induced and dsRNA-activated protein kinase PKR (Chang et al., 1992) . In addition, the VV K3L protein has sequence similarity with eukaryotic initiation factor 2a (elF2a) that is phosphor-ylated and inactivated by PKR (Beattie et al., 1991) . The K3L protein competitively binds PKR and hence blocks the phosphorylation and inactivation of host elFPa. However, these mechanisms can only block the IFN response within infected cells, and to suppress cytokine responses more broadly, poxviruses use other strategies, such as the expression of soluble cyto-A 80 100 B kine receptors. Myxoma virus, a leporipoxvirus, expresses an IFNy receptor that binds and inhibits rabbit IFNy (Upton et al., 1992) , and the otthopoxviruses vaccinia, cowpox, and camelpox encode a soluble IFNy receptor of broad species specificity (Alcami and Smith, submitted) . Myxoma virus expresses a tumor necrosis factor (TNF) receptor that contributes to virus virulence , and Shope fibroma virus and cowpox virus (Hu et al., 1994 ) also encode a soluble TNF receptor. VV and cowpox virus secrete an IL-l p receptor (a member of the immunoglobulin superfamily [IgSF] ) that modulates the host response to infection (Alcami and Smith, 1992; Spriggs et al., 1992) . VV gene B18R also encodes an IgSF member that is distantly related to B15R and the IL-1 and IL-8 receptors (McMahan et al., 1991; Smith and Chan, 1991) but fails to bind either cytokine (Alcami and Smith, 1992; Spriggs et al., 1992; Morikawa and Ueda, 1993) . Here, we demonstrate that B18R encodes a soluble type I IFN receptor with high affinity for human type I IFN. This receptor contributes to VV virulence, has novel broad species specificity, and belongs to a protein superfamily different from those of other type I IFN receptors.
Results

Vaccinia Virus Encodes a Soluble IFNa Inhibitor
To determine whether VV encoded a soluble inhibitor of type I IFN, virus-free supernatants from mock-infected or VV strain Western Reserve (WR)-infected ceils were incubated with increasing concentrations of human natural IFNa on HeLa cells, and these cells were subsequently challenged with coca1 virus, a rhabdovirus similar to vesicular stomatitis virus. Figure 1A shows that cells infected with coca1 virus were lysed, but IFNa at 220 U/ml protected cells from this cytopathic effect (CPE). However, cultures To investigate how widely the IFNa inhibitor was distributed in orthopoxviruses, cells were infected with 14 VV strains (including rabbitpox and buffalopox), two strains of cowpox virus (Brighton red and elephantpox) and camelpox virus, and the cell supernatants were tested for inhibition of IFNa activity (Figure 1 B) . Inhibitory activity was found in all VV strains except Lister, but the activity was low in strain Wyeth. The lack of activity with strain Lister and the low level of activity with strain Wyeth were not due to a poor infection, as supernatants from Lister-, Wyeth-, or WR-infected cells inhibited IFNy to a similar extent (data not shown). Cowpox, elephantpox, and camelpox also expressed an inhibitor of type I IFN, although this was at very low levels with camelpox.
Mapping of the Soluble IFNa Inhibitor
To map the VV gene encoding the soluble IFNa inhibitor, we used viruses v6/2 (Moss et al., 1981) , vGS100, and vSSK2 (N. W. Blake, K. M. Law, S. Kettle, and G. L. S., unpublished data), which have large deletions in the lefi or right ends of the genome (Figure 2A ). These regions were selected for study because other VV genes that express soluble modulators of the immune response to infection are encoded here (Smith, 1993) . Supernatants from cells infected with these viruses were tested for their ability to inhibit the bioactivityof human natural IFNa or recombi- nant IFNY. Figure 2B shows that supernatants from cells infected with WR, v6/2 (a strain of VV WR with a 9 kb deletion near the left inverted terminal repeat [ITRJ), or vGSlO0 (a strain of VV WR lacking gene B22R and all genes rightward up to the gene encoding a 7.5 kDa polypeptide within the right ITR) inhibited the biological activity of IFNa. However, supernatants from vSSK2 (a strain of VV WR lacking genes B13R to 821 R in addition to those missing in vGS100) did not inhibit the bioactivityof IFNa. In contrast, all four virusesexpressed asoluble IFNy receptor encoded by gene B8R (Alcamf and Smith, submitted). Thus, the gene encoding the IFNa inhibitor mapped between B13R and B21R.
This region contains only two genes, B15R and B18R, predicted to encode secreted proteins (Smith and Chan, 1991; and B15R encodes a soluble IL-16 receptor (Alcami and Smith, 1992; Spriggs et al., 1992) . To determine whether B15R or B18R encoded the IFNa inhibitor, supernatants from cells infected with viruses lacking either gene, vAB15R or vABl8R (Alcami and Smith, 1992) were tested for inhibition of IFN activity ( Figure 2C ). Supernatants from WR and vAB15R inhibited both type I (IFNa and IFN8) and type II IFN (IFNy) activity, but those from vAB18R-infected cells inhibited only IFNy activity. This result was confirmed by using supernatants from Spodoptera frugiperda (S9 insect cells infected with recombinant baculoviruses expressing either B15R or B18R (Alcami and Smith, 1992) or B8R, a gene encoding a soluble IFNy receptor (Alcami and Smith, submitted) . Supernatants containing B18R (AcB18R) inhibited type I IFN, and those containing B8R (AcB8R) inhibited type II IFN, whereas B15Rcontaining supernatants(AcB15R) inhibited neither type of IFN. Gene B18R, therefore, encodes a type I IFN inhibitor.
The Bl8R Protein Blocks the Binding of IFNa to Its Cell Surface Receptor
The biological inhibition of type I IFN mediated by B18R might occur by degradation of IFNa or by blocking either the binding of IFN to cell receptors or some step of the IFN-responsive signaling pathway. The possible degradation of IFN was eliminated by the observed stability of 'zl-IFNa2 in the presence of the B18R protein (data not shown). Next, the potential of B18R to block IFNa2 binding to its cell receptor was investigated. Figure 3A shows that human '251-IFNa2 specifically bound to atype I IFN receptor on U937 cells, and this binding was inhibited by cold IFNa and IFNf3, but not by IFNY. Similarly, supernatants from mammalian cells infected with WR and vAB15R, but not from uninfected or vAB18R-infected cells, and supernatants from insect cells infected with recombinant baculovirus AcB18R, but not AcB6R or AcB15R, inhibited the binding of the IFN to U937 cells. The B18R protein, therefore, blocks binding of type I IFN to its cell receptor.
The B18R Protein Binds Type I IFN The above result suggested that the B18R protein might bind to type I IFN. This was tested in soluble binding assays with human '%I-IFNa2 ( Figure 38 ). Supernatants from WR-infected cells bound to IFNa2, and the specificity of this binding was shown by its inhibition with cold human type I IFNs but not with type II IFN. B18R was confirmed as the IFN-binding protein by the binding of '251-IFNa2 to supernatants from cells infected with WR and vAB15R but not vAB18R. In addition, supernatants from cells infected with recombinant baculovirus AcB18R, but not Ac68R or AcB15R specifically bound the 1251-IFNa2. These results demonstrated that B18R was a novel soluble receptor for type I IFN.
Characterization
of the B18R Gene Product Previously, the B18R gene was shown to be transcribed and translated early during infection (Ueda et al., 1990; AlcamiandSmith, 1992) . This wasconfirmed byobserving that supernatants from cells infected with VV WR in the presence of cytosine arabinoside (an inhibitor of DNA synthesis and VV late gene expression) also contained an IFNa inhibitory activity (data not shown). The size of the B18R protein has been reported as either 40 kDa when translated in vitro (Ueda et al., 1990) or 80-65 kDa when secreted from VV-infected cells (Alcami and Smith, 1992) . This was further analyzed by ligand blotting (Figure 4) . Supernatants from either W-or recombinant baculovirusinfected cells were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) under nonreducing conditions, blotted onto nitrocellulose, and probed with '251-IFNa2 with or without cold competitors. The supernatant from cells infected with WR but not vABl8R contained a protein that bound '251-IFNa2 and migrated at approximately 59 kDa ( Figure 4A ). An identically sized protein was detected after infection with all orthopoxviruses tested except W strains Lister, Wyeth, and camelpox (data not shown). Recombinant baculovirus-derived B18R, but not B8R or B15R, also bound to '251-IFNa2; however, the molecule migrated at 38 kDa (Figure 4B) , consistent with the smaller size of the B18R protein (48 kDa) expressed from insect cells (Alcami and Smith, 1992; Morikawa and Ueda, 1993 Figure 5A ) and 1.13 x 10" f 0.05 x lo4 binding sites secreted during 24 hr per infected cell. This affinity is similar to that reported for human IFNaA and the type I IFN receptor on human U937 cells (KD, 300 PM) (Langer and Peska, 1986) and to our data (not shown) indicating 3.6 x lo3 high affinity sites with a KD of 440 pM on U937 cells. The B18R protein secreted from insect cells (Figure 58 ) had a 3-fold lower affinity (KD, 527 f 40 PM) than the VV W&derived protein, but the number of binding sites produced during a 72 hr infection was much greater (2.27 x lo6 f 0.11 x 106), reflecting the high level of expression in the baculovirus system. Because W strain Wyeth produced only low IFNa-inhibitory activity (Figure lB) , we assessed whether this was due to low receptor expression or low affinity for the ligand. Scatchard analysis ( Figure 5C ) revealed a similar number of binding sites per cell (1.50 x lo4 f 0.06 x 103 compared with the number for WR, but with a KD of only 13.5 f 0.83 nM, 76-fold lower than the WR B18R protein.
Species Specificity of the VV Type I IFN Receptor The relative binding affinities of B16R for type I IFN from different species were compared by competition binding of unlabeled IFNs with human '251-IFNa2. Equilibrium dissociation constants were calculated from the ECso values using the Cheng-Prusoff relationship (Cheng and Prusoff, 1973) . These calculations were based on a KD of 174 pM for the binding of human 1z51-IFNa2 to the WR B18R protein ( Figure 5A ) and could only be performed where the competitor contained only one subtype of IFN. The competitive binding curves ( Figure 6A ) revealed that type I IFN from different species bound to the WR B18R protein with varying affinities. Human and rabbit type I IFN bound to B16R with indistinguishable high affinity, and bovine and rat IFNa bound with reduced affinity, with an estimated KD in the case of bovine IFNal of 1 nM, whereas mouse type I IFNs bound with low affinity, with an estimated KD of 27 nM for mouse IFNf3. To analyze further the species specificity of the WR type I IFN receptor, the ability of supernatant from W&infected cells to inhibit type I IFN bioactivity from a number of different species was examined. Figure 66 shows that l318R inhibits type I IFN activity from all species tested, but in agreement with the binding data, human and rabbit IFN were inhibited most effectively, with supernatant from only lo3 cells causing complete inhibition of 5 U of IFN. Rat and bovine IFN were inhibited less efficiently, requiring supernatants from 104 cells to inhibit the activity of 5 U of IFN, and the supernatant from lo5 cells was required to cause complete inhibition of 5 U of mouse IFN. In all cases, supernatants from vAB18Rinfected cells tested at the same concentrations mediated no inhibition of the IFN activity (data not shown).
Virulence of VV Lacking B18R in Mice
The contribution of B18R to VV virulence was tested in a murine intranasal model (Turner, 1967; Williamson et al., 1990) in which at doses of >/lo4 plaque-forming units (pfu) of VV WR, there is an extensive respiratory infection, followed by virus dissemination and death. To be certain that any difference observed in the phenotype of WR and vAB18R was due only to loss of B18R, a virus revertant, vB18R-R, was constructed by transient dominant selection (Falkner and Moss, 1990; lsaacs et al., 1990) in which the B18R gene was reinserted into the endogenous locus of the vAB18R genome. The viruses vABl8R and vB18R-R did not contain the selective marker that might affect their phenotype. The correct structure of the B18R gene and flanking genes in vB18R-R was confirmed by Southern blot hybridization and polymerase chain reaction (PCR) as described in Experimental Procedures (data not shown), and the expression of an active B18R gene was confirmed by binding assays with human 1z51-IFNa2 (data not shown). Table 1 shows that deletion of gene B18R reduced VV virulence. At doses of lo4 and lo5 pfu, most mice infected with WR or vB18R-R were sacrificed, owing to a severe infection and the loss of 230% of body weight, while vABl8R-infected animals survived. The attenuation of the virus was most clearly illustrated at a dose of 100 pfu, where mice infected with vAB18R showed no sign of ill- ness (ruffled fur, arched backs, or reduced mobility) and lost only a maximum of 5% of body weight ( Figure 7A ). In contrast, animals infected with WR or vB18R-R showed severe signs of illness and weight loss, and many were either sacrificed or died. Similarly, infection with lo5 pfu was very severe with WR and vB18R-R (all animals died or were sacrificed), and although all vAB18R-infected animals showed signs of illness and weight loss, they recovered.
The replication of VV in the lungs and brains of mice on days 5 and 7 after infection was also investigated (Figure 78) . Only three out of eight vAB18R-infected mice had detectable virus in the lungs. In contrast, all eight mice infected with WR and seven out of eight mice infected with vB18R-R yielded virus and yielded it at higher titers than did the vAB18R-infected animals. Dissemination of vAB18R within the infected animal was even more restricted, and on day 5, no virus was detected in the brain, whereas all mice infected with WR or vB18R-R yielded virus. The type I IFN receptor, therefore, contributes to VV virulence in this model.
Discussion
This study demonstrates that most orthopoxviruses express a soluble receptor for type I IFNs, which in VV strain WR is encoded by gene B18R. This gene was predicted to encode a secretory IgSF glycoprotein with similarity to another W IgSF protein, B15R, and to the IL-1 and IL-6 receptors (McMahan et al., 1991; Smith and Chan, 1991) . The B15R protein was later shown to be a 50-60 kDa soluble IL-10 receptor (Alcami and Smith, 1992; Spriggs et al., 1992) , while B18R encodes a 60-65 kDa glycoprotein that is expressed on the cell surface and is secreted from the cell (Ueda et al., 1990; Alcami and Smith, 1992; Morikawa and Ueda, 1993) . Although B18R has 20% amino acid identity with B15R, it does not bind IL-1 or IL-6, and its ligand had hitherto not been identified (Alcami and Smith, 1992; Morikawa and Ueda, 1993) . B18R was known, however, to encode the S antigen that is expressed by most orthopoxviruses, but not VV strain Lister (Ueda et al., 1969; Ueda et al., 1972; Amano et al., 1979; Ueda et al., 1990; Morikawa and Ueda, 1993) . It is surprising that B18R is a type I IFN receptor, as it is an IgSF member, while other type I IFN receptors are CRF2 members (Callard and Gearing, 1994) .
Characterization of the VV WR type I IFN receptor showed that the protein is expressed early during infection and has higher affinity for human IFNa and IFNP (Ko, 174 PM) than do the human type I IFN receptors (200 pM to 5 nM). This is consistent with the VV WR type I IFN receptor being an effective competitor for IFN binding in vivo. Cells infected with VV secreted 1 .l x lo4 type I IFN receptors per cell, lower than the number of IL-lp receptors (1 x lo5 per cell) produced by the same virus (Alcami and Smith, 1992) . This difference may be partly attributable to expression from an early (B18R) rather than a late (B15R) promoter, but may also reflect the retention of some B18R on the cell surface (Ueda et al., 1990; Alcami and Smith, 1992; Morikawa and Ueda, 1993) . Whether B18R present on the cell surface can still bind type I IFN is under investigation.
The affinity of the baculovirus-derived B18R was 3-fold lower than that of the VV WR B18R, and, consistent with its higher affinity, VV WR B18R inhibited IFN binding to U937 cells more effectively than did baculovirus-derived B18R. This lower affinity may be due to the incomplete glycosylation of the B18R protein from insect cells. The sizes of the B18R protein derived from insect and mammalian cells (38 and 59 kDa, respectively) detected by ligand blotting under nonreducing conditions ( Figure 4 ) were broadly consistent with the sizes observed from these cells (48 and 60-65 kDa, respectively) by immunoprecipitation and electrophoresis under reducing conditions (Alcami and Smith, 1992) . The different running conditions may explain the different sizes observed. The size of the B18R type I IFN receptor was shown by ligand blotting to be highly conserved in orthopoxviruses (data not shown).
The VV strain Wyeth type I IFN receptor has 78-fold lower affinity for human INFa than does the WR-derived protein, while the proteins were expressed at similar levels. The sequence of the B18R gene in VV Wyeth will, therefore, be of interest. The lack of expression of a type I IFN receptor by VV Lister was consistent with the previous observation that this virus does not express the S antigen (Amano et al., 1979) , which was shown to be encoded by gene B18R (Ueda et al., 1990) . It is also noteworthy that Wyeth, which expresses a low affinity receptor, and Lister, which expresses no receptor, were widely used smallpox vaccines that gave lower frequencies of postvaccinial neurological complications than many other strains (Fenner et al., 1988) . Possibly the lack of a high affinity soluble receptor for human type I IFN contributed to the relative safety of these vaccine strains.
With the exception of the binding of human type I IFN to bovine IFN receptors, the type I IFNs demonstrate a strict species specificity even to the degree that mouse and rat IFNs cross-react poorly. The broad species specificity of the type I IFN receptor from W is therefore remarkable. This might be because the W receptor is an IgSF rather than a CRF2 member, and this may permit greater structural flexibility to confer the broad specificity. The VV type I IFN receptor has a very high affinity for human IFNa and IFNP (KD, 174 PM) and rabbit type I IFN, a high affinity for bovine (Ko, 1 nM) and rat type I IFN, and an affinity for mouse IFNP (KD, 27 nM) 150-fold lower than that for human IFNa. Nevertheless, this affinity is still sufficient for the receptor to bind and inhibit mouse IFNa, and, consonant with this, the virus lacking the B18R gene was attenuated in intranasally infected mice.
The relative affinities of the VV type I IFN receptor for type I IFN from different species are relevant to the enigmatic origin of VV and which host(s) this virus might have naturally infected during evolution. Jenner introduced cowpox for vaccination against smallpox in 1798, but the smaHpox vaccines used this century are VV, not cowpox (Downie, 1939) . Thus, sometime between 1798 and 1939, VV replaced cowpox as the smallpox vaccine. Molecular analyses of the genomes of cowpox, VV, and variola (Mackett and Archard, 1979; Goebel et al., 1990; Aguadoet al., 1992; Shchelkunovet al., 1993; Massung et al., 1994) have shown that VV is unlikely to have arisen by mutation from cowpox or variola or by recombination between these viruses, and a favored hypothesis for the origin of VV is that it is an independent orthopoxvirus that previously infected a species in which it is no longer endemic. Horsepox has been suggested (Baxby, 1981) , as early vaccinators were reported to obtain supplies of vaccine from poxvirus infections of horses when supplies from infected cows were scarce. The affinities of the VV type I IFN receptor for IFN from different species indicate that the mouse is less likely than human, rabbit, cow, or rat to have been a natural host. Consistent with this, an analysis of the species specificity of the W and cowpox IFNy receptor showed that these bound and inhibited the activity of lFNy from human, cow, and rat, but not mouse (Alcami and Smith, submitted) .
The importance of IFN for protection against virus infection is illustrated by the consequences of direct IFN treatment and the inactivation of components of the IFN sys-tern, but also by the numerous measures taken by viruses to counteract IFN (introduction).
Many viruses, including VV, achieve resistance to IFN by targeting the intracellular IFN-induced enzyme PKR (for review, see Smith, 1994) . But poxviruses also present an extracellular blockade of type II (Upton et al., 1992; Alcami and Smith, submitted) and type I (this paper) IFNs. The latter represents a novel mechanism for VV inhibition of type I IFN, the fourth VV protein that interferes with IFN and the fourth soluble cytokine receptor identified in poxviruses.
Deletion of the poxvirus cytokine receptors has variable effects on virus virulence. Loss of the TNF receptor from myxoma virus attenuated the virus in rabbits . Inactivation of the IL-lb receptor from VV caused a 100-fold increase in LDso when inoculated intracranially into mice (Spriggs et al., 1992) . In contrast, intranasal infection, a more physiologically relevant route, with vABl5R caused an increase in virulence (Alcami and Smith, 1992) . The effect of deletion of the IFNy receptor on virulence is unknown. Here, deletion of the IFNalP receptor from VV WR is shown to attenuate VV in a murine intranasal model and to diminish virus replication in the lungsand dissemination to the brain. The degree of attenuation observed in this model is modest compared with that resulting from deletion of structural proteins of the envelope of extracellular enveloped virus (Engelstad and Smith, 1993; Parkinson and Smith, 1994) . This may reflect the relatively low affinity of the VV type I IFN receptor for mouse type I IFN, and the retention by the Bl8R deletion mutant of other genes (E3L and K3L) that confer resistance to IFN. The VV type I IFN receptor shares 89% amino acid identity with an open reading frame (ORF) in variola major virus strains India-1967 and Bangladesh-1975 (Massung et al., 1993 , 1994 Shchelkunov et al., 1993) . Such a high degree of amino acid identity makes it probable that the variola protein would bind IFN with similar species specificity and would have contributed to variola virus virulence in humans.
Other soluble cytokine receptors expressed by poxviruses (for TNF, IL-1 p, and IFNy) were recognized only after the sequencing of mammalian homologs, owing to their amino acid identity (24%-380/o) with the extracellular ligand-binding domains of the cellular receptors. In contrast, no mammalian homolog has been described for the VV type I IFN receptor. Preliminary analysis does not show any significant sequence similarity of Bl8R with the extracellular domain of the known human IFNalP receptors. However, the similar folding pattern of fibronectin type Ill and immunoglobulin domains (Barclay et al., 1993 ) may facilitate the interaction of two unrelated receptors with type I IFNs. If Bl8R has been acquired from the host, as seems likely for other poxvirus cytokine receptors, the sequence of the Bl8R gene may aid the cloning of a cellular counterpart. Such a host protein might be a soluble inhibitor of IFN action or a cell surface agonist or antagonist. Although an analysis of human serum IFN-binding proteins only identified a soluble-form of the 51 kDa IFN type I receptor (Novick et al., 1992 (Novick et al., , 1994 , cross-linking of radiolabeled IFNa to cell surfaces identified multiple complexes (Colamonici et al., 1992) . In summary, we have shown that the orthopoxviruses encode a high affinity IFNalP receptor of novel structure and broad species specificity. The presence of an IFNa/P receptor in the orthopoxvirus genome adds to the impressive array of anti-IFN mechanisms employed by the virus and emphasizes the importance of IFN in defense against viruses. Lastly, this study illustrates that the analysis of virus immune evasion mechanisms may reveal potentially novel components of the mammalian immune system as well as imparting fundamental information about virus pathogenesis. 
Experimental Procedures
Cytoklnes
Human recombinant IFNa2 (specific activity, 3 x 1 O8 Ulmg) was obtained from PeproTech (London, England) and was radioiodinated without loss of biological activity by using '*? Bolton-Hunter reagent (specific activity, 2000 Cilmmol; Amersham, England) to a specific activity of 40 pCi/ug (Langer and Peska, 1986) . Human natural IFNa (specific activity, 1.5 x 108 Ulmg) derived from Namalwa cells was obtained from Wellcome (Beckenham, England), human recombinant lFN6 (specific activity, 2 x 108 Ulmg) from GIBCO BRL, mouse IFNa and lFN6 (specific activity, 4 x 10' Ulmg and 1.3 x 1 Oe Ulmg, respectively) from Calbiochem, and recombinant human and mouse IFNy (1 x 10' Ulmg) from Genzyme; bovine recombinant IFNal (specific activity, 1 x 10' Ulmg) was a generous gift from R. A. Collins (Institute of Animal Health, Compton, England); and rat and rabbit type I interferon (specific activity, 1.9 x lo1 Ulmg and 3.9 x 10" U/mg, respectively) were from Lee Biomolecular Research Laboratories, Incorporated (San Diego, California).
Preparation
of Supernatants from Virus-Infected Cells Cultures of TK-143B cells or Sf cells were infected with 10 pfulcell. Supernatants from orthopoxvirusor baculovirus-infected cells were harvested 3 days postinfection and centrifuged at 3000 rpm for 10 min at 4OC and the pellet discarded.
Virus particles were removed by centrifugation at 16,500 rpm in a SW41 Ti rotor for 60 min at 4OC. The supernatants were then concentrated to that equivalent to 3 x 10' cells/ml in Centriprep-10 concentrators (10,000 MW cutoff; Amicon) and stored at -2OOC.
Biological
Assays for IFN The biological activity of IFN from different species was assayed by its ability to inhibit coca1 virus plaque formation (Alcami and Smith, submitted) .
Human, mouse, bovine, rat, and rabbit IFN were assayed in cultures of human HeLa cells, mouse L929 cells, bovine MDBK cells, rat NRK cells, and rabbit RK13 cells, respectively.
Cell monolayers in 24-well-plates (Nunc) were pretreated in 0.5 ml of MEM containing 10% FBS and the indicated doses of IFN and supernatants from orthopoxvirusor recombinant baculovirus-infected cultures.
After an 16 hr incubation at 37"C, the cells were infected with approximately 100 pfu of coca1 virus and the cells incubated for a further 48 hr at 37OC in media containing 1.5% (w/v) carboxymethylcellulose.
The percentage (Dower et al., 1985) and the tube tips excised and radioactivity counted in a gamma counter. Soluble receptor binding assays were performed in duplicate with supernatants from W-or baculovirus-infected cells by incubation with 'ZSI-IFNa2 in a final volume of 0.2 ml for 90 min at room temperature. The ligand receptor complexes were precipitated with polyethylene glycol (PEG) and the precipitate collected on Whatman GF/C filters as described (Symons et al., 1990) . Nonspecific binding of '251-IFNa2 precipitated with binding medium alone was subtracted. Binding data were analyzed with the LIGAND program (Munson and Rodbard, 1980) .
Ligand Blotting
Supernatants from lo5 VV-or lo4 baculovirus-infected cells were resolved by SDS-PAGE under nonreducing conditions on a 7.5% gel and transferred onto 0.45 pM nitrocellulose (Schleicher and Schuell). After the filters were blocked in 3% (w/v) nonfat skimmed milk in 10 mM Tris-HCI (pH 7.4) 140 mM NaCI, 0.02% (w/v) NaN, overnight at 4°C the filters were probed with 10 nglml '251-IFNa2 in blocking buffer with or without 1 .O uglml cold IFN for 4 hr at room temperature. Blots were then washed three times for 30 min in blocking buffer, air-dried, and exposed to autoradiography film.
Construction of Recombinant
Vaccinia Viruses The W WR B16R deletion mutant, vAB16R (Alcamiand Smith, 1992 ) was used for the construction of a revertant virus containing the B16R gene in its endogenous locus by transient dominant selection (Falkner and Moss, 1990; lsaacs et al., 1990) . A plasmid, pAA21, was constructed in which a BamHI-Xbal DNA fragment, excised from pAA (Alcami and Smith, 1992) and containing the entire B16R gene and 360 and 690 nt of the 5' and 3' flanking regions, respectively, was cloned into BamHI-and Xbal-cut pSJH7 (Hughes et al., 1991) . This plasmid was transfected into cells infected with vAB16R, and after isolation of mycophenolic acid-resistant intermediate viruses, a revertant was isolated on D960R cells (Kerr and Smith, 1991) by using bthioguanine (Isaacs et al., 1990) . The virus revertant isolated was termed vAA15 and is referred to here as vB16R-R.
The genomes of vAB16R and vB16R-R were analyzed by using virus DNA extracted from virus cores (Esposito et al., 1961) . Viral DNA was cut with three different enzymes and analyzed by Southern blotting using fluorescein-labeled probes specific for B16R and the right hand end of the genome. PCR analyses using oligonucleotides flanking the B16L, B17R, B16R, B19R, and B20R ORFs of W WR were also performed.
These analyses confirmed that the genomic structure of each virus was as expected and that no other alterations had occurred at the right hand end of the virus genome (data not shown).
Recombinant
Baculovirus The recombinant baculoviruses expressing B15R (AcAA3). B18R (AcAA4), and B8R (AcAA5) are described elsewhere (Alcami and Smith, 1992; Alcami and Smith, submitted) and are referred to here as AcB15R
AcB18R, and AcBBR, respectively.
Assay of Virus Virulence
Female BALB/c mice (5-6 weeks old) were anesthetized and infected intranasally with 20 ul of the diluted virus in 0.5% bovine serum albumin in phosphate-buffered saline (Turner, 1967; Williamson et al., 1990) . Each day, mice were individually weighed and monitored for signs of illness, and those suffering a severe infection and having lost > 30% of body weight were sacrificed.
To determine virus titers in organs, mice were sacrificed 5 or 7 days postinfection and their lungs and brains removed, weighed, dounce homogenized in 1 ml of phosphate-buffered saline, frozen and thawed three times, and sonicated. Virus infectivity was determined by plaque assay on BS-C-l cells.
